Skytrofa

Skytrofa (lonapegsomatropin), Ascendis Pharma's once-weekly recombinant growth hormone, was approved in 2021 for pediatric growth hormone deficiency (GHD) and expanded to adult GHD in July 2025 [2][3]. The label-expansion play is shows (NCT07221851), a Phase 3 basket trial against daily somatropin in four short-stature populations that currently rely on daily injections: Turner Syndrome, SHOX deficiency (a bone-growth gene disorder), small-for-gestational-age (SGA) children with growth failure, and idiopathic short stature (ISS) [1][4]. The trial enrolls 186 patients and reads out on annualized height velocity, the same endpoint that carried Skytrofa across the finish line in pediatric and adult GHD [5]. The single most important recent development: in March 2026, the InsiGHTS Phase 2 in Turner Syndrome reported 52-week data showing LS mean height velocity of 9.05 cm/year with lonapegsomatropin versus 9.04 cm/year with daily somatropin, essentially identical [6]. That result substantially derisks the Turner arm of shows and by extension the basket. Skytrofa generated approximately $263M in 2024, up roughly 80% year-over-year, and the July 2025 adult GHD approval added a second growth vector before the basket even reads out [7]. The bet is on convenience translating into similar growth, not on new biology, and the Phase 2 Turner data says convenience is holding.

Skytrofa was approved in August 2021 for pediatric GHD (BLA 761177) [2]. On July 28, 2025, FDA approved the adult GHD indication based on the foresiGHt Phase 3, a placebo- and active-controlled trial of 259 patients aged 23 to 81 randomized 1:1:1 to weekly lonapegsomatropin, weekly placebo, or daily somatropin [3][5]. The current expansion is shows (NCT07221851), a Phase 3 basket trial that opened in 2025 and is now recruiting, sponsored directly by Ascendis Pharma A/S [1][4]. It runs alongside InsiGHTS (NCT05690386), the Phase 2 Turner Syndrome dose-finding study whose 52-week topline data reported March 17, 2026 showed comparable efficacy and safety to daily somatropin (annualized height velocity 9.05 vs 9.04 cm/year, n=49, ages 1 to 10) with adverse events mild to moderate through 143 weeks of follow-up and no cases of slipped capital femoral epiphysis [6]. No publicly disclosed breakthrough, fast-track, or accelerated-approval designations attach to the basket. Ascendis also runs two long-term safety studies (NCT05820672 US non-interventional, NCT05775523 EU post-authorization) because the growth hormone class carries a mandatory neoplasm surveillance requirement [8][9]. Primary endpoint for shows is annualized height velocity at 52 weeks. With enrollment ramping through 2026, a top-line readout is realistic in 2027 to early 2028, with regulatory submission plausible in 2028 to 2029 if the data supports non-inferiority against daily somatropin.

Growth hormone (GH) is a pituitary hormone the body releases in pulses, mostly overnight, that drives childhood growth and maintains adult metabolism. It binds the growth hormone receptor (GHR) on liver and other tissues, activates the JAK2/STAT5 signaling pathway, and triggers IGF-1 release, which is the direct driver of bone lengthening. Children with GHD, Turner Syndrome, or SHOX deficiency either make too little GH or their tissues respond poorly to it, and daily injections of recombinant human growth hormone (somatropin) have been the treatment since 1985. SHOX (Short Stature Homeobox) is a transcription factor gene on the sex chromosomes; it drives long-bone growth plate activity, and mutations cause short stature by impairing the growth plate itself, not by disrupting GH secretion, which is why the GH axis remains partially responsive and pharmacological GH doses can drive linear growth. Lonapegsomatropin is the same somatropin molecule tethered to a PEG (a water-soluble polymer) carrier using Ascendis's TransCon linker chemistry, which slowly releases active drug over seven days. The pharmacology is essentially unchanged. The pharmacokinetics stretch the peak-to-trough profile out over a week instead of a day. Genetic validation of the target is unusually deep: Laron syndrome, caused by loss-of-function mutations in GHR, produces severe short stature and IGF-1 deficiency; GH1 mutations cause pituitary dwarfism; Turner Syndrome patients respond measurably to exogenous GH [10]. The mechanism is not the question. The question was whether weekly dosing gives equivalent height gain to daily dosing in populations where GH sensitivity is already blunted, and Turner Phase 2 data in March 2026 answered that with a yes for at least one of the four basket populations.

shows (NCT07221851) is a Phase 3, open-label, active-controlled basket trial enrolling approximately 186 prepubertal children and adolescents ages 2 to under 18, split across four indications: Turner Syndrome, SHOX deficiency, small-for-gestational-age with growth failure, and idiopathic short stature [1][4]. Patients are randomized 1:1 to one of two regimens: weekly lonapegsomatropin for two years, or daily somatropin for year one followed by weekly lonapegsomatropin for year two. This crossover design lets every enrolled patient end on lonapegsomatropin, which helps recruitment and long-term safety data collection but complicates any pure head-to-head comparison beyond year one. Primary endpoint is annualized height velocity in centimeters per year at 52 weeks, the endpoint FDA has accepted for growth indications since the original somatropin approvals. The design is efficient: one protocol, four indications, one comparator. The trade-off is statistical power inside each subpopulation: with 186 patients split across four groups, individual indication arms are small, and non-inferiority (a regulatory bar where weekly lonapegsomatropin must not fall below a pre-specified minimum threshold of daily somatropin's height velocity effect) requires tight confidence intervals inside each group. The exact non-inferiority margin has not been publicly disclosed by Ascendis; the prior pediatric GHD heiGHt trial used a 2 cm/year margin as a reference point [11]. Trial status is RECRUITING as of mid-2026, running in the US, France, Germany, Italy, Romania, Spain, and South Korea [1]. The parallel InsiGHTS Phase 2 in Turner Syndrome (NCT05690386, n=49) served as the dose-selection anchor and reported 52-week data on March 17, 2026 [6]. That readout was the first real proof point that weekly dosing holds up in a GH-responsive but partially resistant population, and Ascendis used it to lock the Turner dose regimen going into the key basket.

Lonapegsomatropin is FDA-approved (SKYTROFA, 2021-08-25). BioCosm's model estimates a drug's first FDA approval, which has already happened here, so no probability is shown - any current trial is a new-indication study.

Efficacy risk narrowed sharply after the March 2026 InsiGHTS Turner Syndrome 52-week readout: weekly lonapegsomatropin matched daily somatropin at 9.05 vs 9.04 cm/year in the Phase 2 arm most likely to fail if weekly PK were inadequate [6]. Turner is now the closest thing to a positive proof point the basket could have. The remaining efficacy question is SHOX deficiency, where the growth plate defect is skeletal rather than endocrine and the trajectory under weekly PK has not been directly measured. SGA and idiopathic short stature carry less mechanistic risk since these patients generally have intact GH secretion, though non-inferiority margins in small subgroups can still be missed on statistical noise alone. Safety risk is class-based rather than compound-specific. Growth hormone therapy carries long-term concerns around benign and malignant neoplasms, insulin resistance, and scoliosis progression, which is why FDA mandates the two long-term registries [8][9]. FAERS (the FDA Adverse Event Reporting System, which aggregates post-marketing safety reports) data on Skytrofa to date shows the dominant reports are dose omission (107 cases), headache (59), and injection-site pain (48), plus device-malfunction issues tied to the auto-injector, not systemic toxicity signals. Commercial risk is real even with approval. Pfizer's Ngenla (somatrogon) and Novo Nordisk's Sogroya (somapacitan) are both approved weekly GH products with sales infrastructure Ascendis cannot match, and daily somatropin (Norditropin, Humatrope, Genotropin) is entrenched with generic-adjacent pricing pressure. Payers will demand head-to-head non-inferiority or a demonstrated convenience premium to justify a switch from daily to weekly across the pediatric endocrine clinic. Financial risk is modest: Skytrofa revenue plus achondroplasia franchise development are funding Ascendis into the shows readout window per its Q1 2026 filings [12].

The March 2026 InsiGHTS Turner Syndrome 52-week readout is done and it is positive: LS mean height velocity 9.05 cm/year on lonapegsomatropin versus 9.04 cm/year on daily somatropin over 52 weeks in 49 prepubertal Turner patients, with comparable safety extending to 143 weeks and no SCFE cases [6]. That is the strongest possible setup going into shows, because Turner is the population where weekly PK was most at risk of falling short, and it did not. Ascendis is a platform story more than a single-drug story: TransCon is the same delivery chemistry powering navepegritide in achondroplasia and the COACH combination trial (NCT06433557), which reported 52-week combination data with lonapegsomatropin in 2026 [13][14]. Skytrofa revenue reached approximately $263M in 2024 per Ascendis financial reporting, growing roughly 80% year-over-year, and the July 2025 adult GHD approval opens a second growth vector while the basket runs [3][7]. Label expansion is what turns Skytrofa from a niche GHD product into a category redefinition. If shows follows the InsiGHTS trajectory across all four subpopulations, Ascendis becomes the default weekly GH story in pediatric endocrinology, competing directly against Pfizer's Ngenla and Novo Nordisk's Sogroya. The absolute total addressable market across Turner, SHOX-D, SGA, and ISS has not been publicly quantified by Ascendis in a form worth citing here, but combined US and EU pediatric prevalence across these four indications is several multiples of the pediatric GHD population, giving the qualitative expansion story real weight even before precise numbers are pinned down. Next catalyst window: shows primary readout, plausibly 2027 to early 2028, with SHOX-D subgroup performance the tightest single-arm question.